432 related articles for article (PubMed ID: 14643119)
1. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection.
Qurishi N; Kreuzberg C; Lüchters G; Effenberger W; Kupfer B; Sauerbruch T; Rockstroh JK; Spengler U
Lancet; 2003 Nov; 362(9397):1708-13. PubMed ID: 14643119
[TBL] [Abstract][Full Text] [Related]
2. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
[TBL] [Abstract][Full Text] [Related]
3. Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART).
Dold L; Ahlenstiel G; Althausen E; Luda C; Schwarze-Zander C; Boesecke C; Wasmuth JC; Rockstroh JK; Spengler U
PLoS One; 2015; 10(8):e0134158. PubMed ID: 26241854
[TBL] [Abstract][Full Text] [Related]
4. Effect of liver fibrosis on long-term mortality in HIV/hepatitis C virus-coinfected individuals who are evaluated to receive interferon therapies in the highly active antiretroviral therapy era.
Sanmartin R; de Felipe E; Tor J; Sanvicens A; Barluenga E; Martinez E; Muga R; Jou A; Ojanguren I; López JJ; Clotet B; Tural C
AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1235-43. PubMed ID: 22443303
[TBL] [Abstract][Full Text] [Related]
5. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.
Torti C; Lapadula G; Casari S; Puoti M; Nelson M; Quiros-Roldan E; Bella D; Pastore G; Ladisa N; Minoli L; Sotgiu G; Mazzotta F; Lo Caputo S; Di Perri G; Filice G; Tinelli C; Carosi G;
BMC Infect Dis; 2005 Jul; 5():58. PubMed ID: 16018804
[TBL] [Abstract][Full Text] [Related]
6. Risks of non-accidental mortality by baseline CD4+ T-cell strata in hepatitis-C-positive and -negative individuals initiating highly active antiretroviral therapy.
Moore DM; Hogg RS; Braitstein P; Wood E; Yip B; Montaner JS
Antivir Ther; 2006; 11(1):125-9. PubMed ID: 16518968
[TBL] [Abstract][Full Text] [Related]
7. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy.
Tedaldi EM; Baker RK; Moorman AC; Alzola CF; Furhrer J; McCabe RE; Wood KC; Holmberg SD;
Clin Infect Dis; 2003 Feb; 36(3):363-7. PubMed ID: 12539079
[TBL] [Abstract][Full Text] [Related]
8. A tale of two viruses: hepatitis C in the age of HAART.
Alatrakchi N; Koziel MJ
Lancet; 2003 Nov; 362(9397):1687-8. PubMed ID: 14643113
[No Abstract] [Full Text] [Related]
9. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.
Rockstroh JK; Mocroft A; Soriano V; Tural C; Losso MH; Horban A; Kirk O; Phillips A; Ledergerber B; Lundgren J;
J Infect Dis; 2005 Sep; 192(6):992-1002. PubMed ID: 16107951
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus coinfection does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy.
Yacisin K; Maida I; Ríos MJ; Soriano V; Núñez M
AIDS Res Hum Retroviruses; 2008 Jul; 24(7):935-40. PubMed ID: 18593347
[TBL] [Abstract][Full Text] [Related]
11. HIV and hepatitis C co-infection: the role of HAART in HIV/hepatitis C virus management.
Jones M; Núñez M
Curr Opin HIV AIDS; 2011 Nov; 6(6):546-52. PubMed ID: 22001896
[TBL] [Abstract][Full Text] [Related]
12. Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort.
Torti C; Lapadula G; Puoti M; Casari S; Uccelli MC; Cristini G; Bella D; Pastore G; Ladisa N; Minoli L; Sotgiu G; Caputo SL; Bonora S; Carosi G
J Acquir Immune Defic Syndr; 2006 Feb; 41(2):180-5. PubMed ID: 16394850
[TBL] [Abstract][Full Text] [Related]
13. Survival in HIV-infected patients is associated with hepatitis C virus infection and injecting drug use since the use of highly active antiretroviral therapy in the Lyon observational database.
Voirin N; Trépo C; Miailhes P; Touraine JL; Chidiac C; Peyramond D; Livrozet JM; Ritter J; Chevallier P; Fabry J; Allard R; Vanhems P
J Viral Hepat; 2004 Nov; 11(6):559-62. PubMed ID: 15500557
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression.
Chen TY; Ding EL; Seage Iii GR; Kim AY
Clin Infect Dis; 2009 Nov; 49(10):1605-15. PubMed ID: 19842982
[TBL] [Abstract][Full Text] [Related]
15. Highly active antiretroviral therapy-related hepatotoxicity in human immunodeficiency virus and hepatitis C virus co-infected patients with advanced liver fibrosis in Taiwan.
Chou CC; Tsai HC; Wu KS; Sy CL; Chen JK; Chen YS; Lee SS
J Microbiol Immunol Infect; 2016 Aug; 49(4):546-53. PubMed ID: 25440980
[TBL] [Abstract][Full Text] [Related]
16. Acute liver enzyme elevations in HIV-1-infected patients.
Livry C; Binquet C; Sgro C; Froidure M; Duong M; Buisson M; Grappin M; Quantin C; Portier H; Chavanet P; Piroth L
HIV Clin Trials; 2003; 4(6):400-10. PubMed ID: 14628283
[TBL] [Abstract][Full Text] [Related]
17. HIV and hepatitis C coinfection.
Matthews GV; Dore GJ
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1000-8. PubMed ID: 18707597
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study.
Anderson KB; Guest JL; Rimland D
Clin Infect Dis; 2004 Nov; 39(10):1507-13. PubMed ID: 15546088
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.
den Brinker M; Wit FW; Wertheim-van Dillen PM; Jurriaans S; Weel J; van Leeuwen R; Pakker NG; Reiss P; Danner SA; Weverling GJ; Lange JM
AIDS; 2000 Dec; 14(18):2895-902. PubMed ID: 11153671
[TBL] [Abstract][Full Text] [Related]
20. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.
Macías J; Castellano V; Merchante N; Palacios RB; Mira JA; Sáez C; García-García JA; Lozano F; Gómez-Mateos JM; Pineda JA
AIDS; 2004 Mar; 18(5):767-74. PubMed ID: 15075511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
